Drugs / PBP1510
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05141149 | Jun 2023 → Feb 2026 overdue | malignant pancreatic neoplasm | Prestige Biopharma Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-07-09 | Prestige Biopharma Limited | Results Prestige Biopharma Unveils Follow-up Clinical Development Strategy for Pancreatic Cancer Drug Candidate PBP1510 at ESMO GI prestigebiopharma.com ↗
Prestige Biopharma presented early clinical research results for its pancreatic cancer drug candidate PBP1510 (Ulenistamab) at the European Society for Medical Oncology Gastrointestinal Cancers Congress (ESMO GI 2026) and discussed follow-up clinical development strategies with global experts. |
| 2025-08-01 | Prestige Biopharma Limited | Regulatory PPrestige Biopharma Secures European Patent for Pancreatic Cancer Antibody PBP1510 prestigebiopharma.com ↗ |
| 2025-06-04 | Prestige Biopharma Limited | Results Prestige Biopharma Highlights PBP1510 Clinical Progress at ASCO 2025 prestigebiopharma.com ↗
According to preliminary results from the ongoing Phase 1/2a clinical trial, the combination therapy of PBP1510 and gemcitabine demonstrated acceptable tolerability with no dose-limiting toxicities (DLTs) or serious adverse events reported. |
| 2023-03-16 | Prestige Biopharma Limited | Regulatory Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer prestigebiopharma.com ↗
Prestige Biopharma has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for PBP1510 (International Non-proprietary Name: Ulenistamab), for the treatment of unresectable or metastatic pancreatic adenocarcinoma (PDAC) that has relapsed following and/or is refractory to at least one line of prior therapy. |
| 2022-06-27 | Prestige Biopharma Limited | Regulatory Prestige Biopharma Receives FDA Approval for Phase 1/2a Trial of Pancreatic Cancer Drug PBP1510 prestigebiopharma.com ↗
Prestige Biopharma announced on the 27th that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2a clinical trial of its antibody therapeutic candidate, PBP1510, for the treatment of pancreatic cancer. |
| 2022-05-31 | Prestige Biopharma Limited | Regulatory Prestige Biopharma announces International Non-proprietary Name for PBP1510 prestigebiopharma.com ↗
Prestige Biopharma Receives WHO International Nonproprietary Name (INN) for PBP1510: “Ulenistamab” |
All press releases naming this drug 9 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBP1510 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05141149 ↗ |
| Action | Inhibit | “targets and neutralizes PAUF” NCT05141149 ↗ |
| Modality | Monoclonal antibody | “Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb)” NCT05141149 ↗ |
| Route | Intravenous | “administered as a 90-minute intravenous infusion” NCT05141149 ↗ |